REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2017

Jun 6, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-06-02

Reporting Person: Sanofi (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-06-02	Common Stock	P	402	$466.3828	Acquired	23506096	Indirect
2017-06-02	Common Stock	P	400	$468.1	Acquired	23506496	Indirect
2017-06-02	Common Stock	P	2132	$469.8097	Acquired	23508628	Indirect
2017-06-02	Common Stock	P	13544	$470.7248	Acquired	23522172	Indirect
2017-06-02	Common Stock	P	7443	$471.8245	Acquired	23529615	Indirect
2017-06-02	Common Stock	P	5806	$473.0711	Acquired	23535421	Indirect
2017-06-02	Common Stock	P	7068	$473.8843	Acquired	23542489	Indirect
2017-06-02	Common Stock	P	12020	$475.1593	Acquired	23554509	Indirect
2017-06-02	Common Stock	P	6312	$476.1472	Acquired	23560821	Indirect
2017-06-02	Common Stock	P	6507	$478.9431	Acquired	23567328	Indirect
2017-06-02	Common Stock	P	12710	$480.1698	Acquired	23580038	Indirect
2017-06-02	Common Stock	P	15197	$481.1292	Acquired	23595235	Indirect
2017-06-02	Common Stock	P	23490	$482.0789	Acquired	23618725	Indirect
2017-06-02	Common Stock	P	18311	$483.0403	Acquired	23637036	Indirect
2017-06-02	Common Stock	P	4708	$484.0367	Acquired	23641744	Indirect

Footnotes

F1: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F2: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").

F3: Purchase prices range from $465.88 to $466.56 per share, inclusive.

F4: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,842,192 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.

F5: Purchase prices range from $468.01 to $468.29 per share, inclusive.

F6: Purchase prices range from $469.19 to $470.04 per share, inclusive.

F7: Purchase prices range from $470.31 to $470.99 per share, inclusive.

F8: Purchase prices range from $471.43 to $472.25 per share, inclusive.

F9: Purchase prices range from $472.45 to $473.33 per share, inclusive.

F10: Purchase prices range from $473.45 to $474.10 per share, inclusive.

F11: Purchase prices range from $474.50 to $475.49 per share, inclusive.

F12: Purchase prices range from $475.70 to $476.47 per share, inclusive.

F13: Purchase prices range from $478.53 to $479.48 per share, inclusive.

F14: Purchase prices range from $479.54 to $480.51 per share, inclusive.

F15: Purchase prices range from $480.54 to $481.53 per share, inclusive.

F16: Purchase prices range from $481.57 to $482.56 per share, inclusive.

F17: Purchase prices range from $482.57 to $483.50 per share, inclusive.

F18: Purchase prices range from $483.57 to $484.50 per share, inclusive.